Pursuant to the provisions of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions regarding ‘Format on Statement of Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement (QIP) etc’, Ind-Swift Laboratories has confirmed that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants. Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended 31st December, 2025 is given in Annexure A.
The above information is a part of company’s filings submitted to BSE.
